FLT3 and acute myeloid leukemia: While sorafenib is not approved for the treatment of AML, midostaurin is the first FDA- and EMA-approved first-generation FLT3 inhibitor that has shown efficacy in prolonging overall survival (OS), EFS [7], and reduction in relapse rates [20] in FLT3-mutated AML within the large, randomized phase-III RATIFY trial.